1. Home
  2. ASMB vs ALTS Comparison

ASMB vs ALTS Comparison

Compare ASMB & ALTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ASMB
  • ALTS
  • Stock Information
  • Founded
  • ASMB 2005
  • ALTS 1976
  • Country
  • ASMB United States
  • ALTS United States
  • Employees
  • ASMB N/A
  • ALTS N/A
  • Industry
  • ASMB Biotechnology: Pharmaceutical Preparations
  • ALTS
  • Sector
  • ASMB Health Care
  • ALTS
  • Exchange
  • ASMB Nasdaq
  • ALTS NYSE
  • Market Cap
  • ASMB 130.2M
  • ALTS 159.4M
  • IPO Year
  • ASMB 2010
  • ALTS N/A
  • Fundamental
  • Price
  • ASMB $18.14
  • ALTS $7.85
  • Analyst Decision
  • ASMB Strong Buy
  • ALTS
  • Analyst Count
  • ASMB 3
  • ALTS 0
  • Target Price
  • ASMB $33.00
  • ALTS N/A
  • AVG Volume (30 Days)
  • ASMB 41.3K
  • ALTS 298.8K
  • Earning Date
  • ASMB 08-07-2025
  • ALTS 08-18-2025
  • Dividend Yield
  • ASMB N/A
  • ALTS N/A
  • EPS Growth
  • ASMB N/A
  • ALTS N/A
  • EPS
  • ASMB N/A
  • ALTS N/A
  • Revenue
  • ASMB $32,154,000.00
  • ALTS $18,046,000.00
  • Revenue This Year
  • ASMB $0.04
  • ALTS $185.91
  • Revenue Next Year
  • ASMB N/A
  • ALTS $64.93
  • P/E Ratio
  • ASMB N/A
  • ALTS N/A
  • Revenue Growth
  • ASMB 148.33
  • ALTS N/A
  • 52 Week Low
  • ASMB $7.75
  • ALTS $1.29
  • 52 Week High
  • ASMB $19.93
  • ALTS $10.95
  • Technical
  • Relative Strength Index (RSI)
  • ASMB 68.18
  • ALTS 46.63
  • Support Level
  • ASMB $17.45
  • ALTS $6.62
  • Resistance Level
  • ASMB $18.92
  • ALTS $8.14
  • Average True Range (ATR)
  • ASMB 0.87
  • ALTS 1.01
  • MACD
  • ASMB -0.05
  • ALTS -0.30
  • Stochastic Oscillator
  • ASMB 74.68
  • ALTS 34.68

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

About ALTS ALT5 SIGMA CORPORATION

ALT5 Sigma Corp is a fintech company. The company operates in three operating segments: Fintech: provides next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets, Biotechnology: Biotechnology segment is focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties; Corporate and Others: Corporate and Other segment consists of certain corporate general and administrative costs. Company has revenue from Fintech Segment.

Share on Social Networks: